Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.96
(30.67%)
USD 1.96
(30.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 172.6 Million USD | 123.35% |
| 2021 | 77.27 Million USD | 15.03% |
| 2020 | 67.17 Million USD | -10.88% |
| 2019 | 75.38 Million USD | -3.16% |
| 2018 | 77.84 Million USD | -14.38% |
| 2017 | 90.91 Million USD | 45.83% |
| 2016 | 62.34 Million USD | 81.96% |
| 2015 | 34.26 Million USD | 68.65% |
| 2014 | 20.31 Million USD | 26.58% |
| 2013 | 16.04 Million USD | -25.48% |
| 2012 | 21.53 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 152.78 Million USD | -10.83% |
| 2023 Q1 | 171.33 Million USD | -0.74% |
| 2022 Q4 | 172.6 Million USD | 11.59% |
| 2022 Q2 | 143.77 Million USD | 37.97% |
| 2022 Q3 | 154.66 Million USD | 7.58% |
| 2022 FY | 172.6 Million USD | 123.35% |
| 2022 Q1 | 104.2 Million USD | 34.84% |
| 2021 Q4 | 77.27 Million USD | 8.89% |
| 2021 Q1 | 68.89 Million USD | 2.55% |
| 2021 FY | 77.27 Million USD | 15.03% |
| 2021 Q3 | 70.96 Million USD | 2.27% |
| 2021 Q2 | 69.39 Million USD | 0.73% |
| 2020 Q3 | 75.37 Million USD | 3.61% |
| 2020 Q1 | 180.11 Million USD | 138.94% |
| 2020 Q2 | 72.74 Million USD | -59.61% |
| 2020 Q4 | 67.17 Million USD | -10.87% |
| 2020 FY | 67.17 Million USD | -10.88% |
| 2019 Q3 | 81.27 Million USD | -8.83% |
| 2019 FY | 75.38 Million USD | -3.16% |
| 2019 Q4 | 75.38 Million USD | -7.25% |
| 2019 Q2 | 89.14 Million USD | 6.01% |
| 2019 Q1 | 84.09 Million USD | 8.03% |
| 2018 Q2 | 88.2 Million USD | 24.03% |
| 2018 Q1 | 71.11 Million USD | -21.78% |
| 2018 FY | 77.84 Million USD | -14.38% |
| 2018 Q4 | 77.84 Million USD | 4.17% |
| 2018 Q3 | 74.72 Million USD | -15.29% |
| 2017 Q1 | 57.99 Million USD | -6.98% |
| 2017 Q2 | 54.81 Million USD | -5.48% |
| 2017 Q3 | 95.81 Million USD | 74.79% |
| 2017 Q4 | 90.91 Million USD | -5.11% |
| 2017 FY | 90.91 Million USD | 45.83% |
| 2016 Q2 | 41.53 Million USD | 14.15% |
| 2016 FY | 62.34 Million USD | 81.96% |
| 2016 Q3 | 41.2 Million USD | -0.79% |
| 2016 Q4 | 62.34 Million USD | 51.31% |
| 2016 Q1 | 36.38 Million USD | 6.2% |
| 2015 Q2 | 24.58 Million USD | -9.12% |
| 2015 Q4 | 34.26 Million USD | -0.94% |
| 2015 Q3 | 34.58 Million USD | 40.71% |
| 2015 Q1 | 27.04 Million USD | 21.92% |
| 2015 FY | 34.26 Million USD | 68.65% |
| 2014 Q4 | 22.18 Million USD | 9.21% |
| 2014 Q1 | 19.26 Million USD | 11.8% |
| 2014 FY | 20.31 Million USD | 26.58% |
| 2014 Q2 | 16.24 Million USD | -15.67% |
| 2014 Q3 | 20.31 Million USD | 25.02% |
| 2013 Q2 | 13.49 Million USD | 0.0% |
| 2013 Q3 | 16.04 Million USD | 18.95% |
| 2013 FY | 16.04 Million USD | -25.48% |
| 2013 Q4 | 17.23 Million USD | 7.39% |
| 2012 Q4 | - USD | -100.0% |
| 2012 FY | 21.53 Million USD | 0.0% |
| 2012 Q3 | 20.88 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bright Green Corporation | 6.43 Million USD | -2580.914% |
| BioQuest Corp. | 632.89 Thousand USD | -27171.463% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -2356.59% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -4475.659% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | 611.78 Thousand USD | -28112.526% |
| Instadose Pharma Corp. | - USD | -Infinity% |